ATAI — AtaiBeckley Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 2081043 ·
Last close
$5.17
Market Cap
$1.90B
52W High
$5.52
52W Low
$3.57
ADV30
8,753,617
Next earnings
2026-08-13
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 954,000 | — | -30,159,000 | -29,782,000 | 264,877,000 | 43,102,000 | 66,098,000 |
| Dec 2025 | 1,066,000 | — | -39,353,000 | -544,813,000 | 292,723,000 | 85,300,000 | 70,722,000 |
| Sep 2025 | 749,000 | — | -28,407,000 | -61,074,000 | 239,820,000 | 30,402,000 | 79,912,000 |
| Jun 2025 | 719,000 | — | -25,245,000 | -27,729,000 | 189,204,000 | 61,940,000 | 45,279,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-105,924,000
Investing CF
$-119,766,000
Financing CF
$210,697,000
CapEx
$-10,868,000
Dividends Paid
—
Buybacks
$-4,468,000
EPS Diluted TTM
$-2.23
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,390,036,000
Inventory
—
Receivables
$14,709,000
ST Investments
$187,665,000
EBIT TTM
$-663,060,000
Pretax Income TTM
$-663,322,000
Interest Exp TTM
$262,000
Analysts
12
Yahoo Snapshot (yfinance, live)
Total Revenue
$3,488,000
EBITDA
$-121,896,000
Free Cash Flow
$-55,528,624
Enterprise Value
$1,736,795,392
Total Cash
$230,767,008
Total Debt
$5,138,000
Shares Out
368,166,674
Trailing EPS
$-2.84
Book Value
$0.54
ROE
-378.0%
ROA
-33.3%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 4,089,000 | -113,347,000 | -660,047,000 | 292,723,000 | 70,722,000 | — | -102,675,000 |
| Dec 2024 | 308,000 | -102,166,000 | -149,269,000 | 159,387,000 | 42,833,000 | — | -82,437,000 |
| Dec 2023 | 314,000 | -123,026,000 | -40,224,000 | 293,478,000 | 49,162,000 | — | -84,118,000 |
| Dec 2022 | 233,000 | -144,430,000 | -152,385,000 | 305,441,000 | 39,675,000 | — | -104,467,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.45
Max Pain — expiry 2026-07-17
max pain strike: $4.00 · spot: $5.17 · call oi: 9,516 · put oi: 1,432
Expected Move to 2026-07-17:
±$0.47
(9.19%) —
implied range
$4.70 –
$5.65
· ATM straddle on $5.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| HCM | HUTCHMED (China) Ltd | $1.90B | $11.07 | — |
| BCAX | Bicara Therapeutics Inc. | $1.90B | $28.91 | — |
| PGEN | PRECIGEN, INC. | $1.90B | $5.32 | — |
| ZYME | Zymeworks Inc. | $1.89B | $25.88 | — |
| RTEZ | REST EZ Inc. | $1.93B | $70.00 | — |
News headlines (Yahoo Finance, 1h cache)
3 Psychedelic Stocks With Potential Clinical Trial Catalysts
2026-07-10 06:21 · Yahoo
AtaiBeckley set to unlock value from positive depression therapy trial results, says Jefferies
2026-07-07 16:47 · Yahoo
AtaiBeckley Completes VLS-01 Dosing in Phase IIb Depression Study
2026-07-07 14:10 · Yahoo
AtaiBeckley (ATAI) Stock Could Be Overvalued Following Phase 2b Dosing Update
2026-07-07 08:15 · Yahoo
AtaiBeckley (ATAI) Draws Takeover Talk From A Major U.S. Drugmaker
2026-07-07 02:08 · Yahoo
What AtaiBeckley (ATAI)'s Elumina Last-Patient Dosed Milestone Means For Shareholders
2026-07-06 20:11 · Yahoo
AtaiBeckley completes dosing in Phase 2b depression trial, expects topline data in Q4
2026-07-06 12:40 · Yahoo
AtaiBeckley Doses Last Patient in VLS-01 Phase 2b TRD Study; Plans Phase 3 in Major Depressive Disorder
2026-07-06 10:00 · Yahoo
Is AtaiBeckley Stock Worth Buying After Its Stronger Rally in 2026?
2026-07-02 15:28 · Yahoo
AtaiBeckley Reflects a New Push for Rapid-Acting Mental Health Drugs
2026-07-02 15:09 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.